We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PRSO:NASDAQPeraso Inc. Analysis

Data as of 2026-05-23 - not real-time

$1.04

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Peraso Inc. (PRSO) is trading at $1.04, just above its 20‑day SMA (1.001) but below both the 50‑day (1.047) and 200‑day (1.072) averages, signaling a short‑term bearish bias despite a bullish MACD histogram. The stock’s 30‑day volatility is extreme at ~140% and the beta is negative (-0.37), indicating high price swings and an inverse move to the market. Fundamentals are weak: revenue plunged 75% YoY to $9.3 M, operating margins are deeply negative (-257%), and the company posted a net loss with a trailing EPS of -$0.81, resulting in a negative PE ratio. However, cash on hand ($2.67 M) comfortably exceeds debt ($0.16 M) and the firm is guiding Q2 revenue of $1.2 M while diversifying its supply chain after a shipment delay.
The analyst consensus is a “strong buy” with a median target price of $2.75, implying a potential upside of over 160% and an “Extreme Greed” market sentiment. Management emphasizes strategic growth in mmWave and defense/Edge AI markets, and the company’s low market cap ($15 M) combined with a price‑to‑sales of 1.65 suggests the stock may be undervalued relative to its long‑term addressable market.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below 50‑day and 200‑day SMAs indicating bearish momentum
  • Extreme short‑term volatility and large recent drawdown
  • Revenue decline and negative operating margins

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Q2 revenue guidance and supply‑chain diversification
  • Strategic focus on high‑growth mmWave and defense applications
  • Analyst target price suggesting >160% upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term secular demand for mmWave and Edge AI technologies
  • Strong cash position relative to minimal debt
  • Undervalued valuation multiples compared to growth potential

Key Metrics & Analysis

Financial Health

Revenue Growth-75.10%
Profit Margin-73.00%
P/E Ratio-6.3
ROE-165.40%
ROA-66.21%
Debt/Equity3.45
P/B Ratio2.3
Industry P/E39.5

Technical Analysis

TrendBearish
RSI51.8
Support$0.92
Resistance$1.59
MA 20$1.00
MA 50$1.05
MA 200$1.07
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Target Price$2.75
Upside/Downside164.42%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta-0.37
Volatility139.88%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.